Subscribe: Market Wire - Medical and Healthcare: Surgery and Treatments
http://img.marketwire.com/rss/mwMHSU.rss
Preview: Market Wire - Medical and Healthcare: Surgery and Treatments

Marketwired - Surgery and Treatments



Marketwired - Surgery and Treatments



Last Build Date: Tue, 13 Feb 2018 09:02:21 EST

Copyright: Copyright: (C) Marketwired
 



American Urological Association (AUA) Honors Imagin Medical Scientific Advisor

Tue, 13 Feb 2018 08:30:00 EST

VANCOUVER, BC and BOSTON, MA--(Marketwired - February 13, 2018) - Imagin Medical (CSE: IME) (OTC PINK: IMEXF) (FRANKFURT: DPD2) (STUT: DPD2) (the "Company"), announced today that the lead investigator on the research study currently underway at the University of Rochester Medical Center using the Company's i/Blue Imaging System is being recognized for his career achievements.




Viveve Announces Closing of Public Offering of Shares of Common Stock

Mon, 12 Feb 2018 11:00:01 EST

ENGLEWOOD, CO--(Marketwired - February 12, 2018) - Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced the closing of its previously announced underwritten public offering of 11,500,000 shares of its common stock at a public offering price of $3.00 per share, including shares of common stock issued upon the full exercise by the underwriters of their option to purchase additional shares. The net proceeds to Viveve from the offering were approximately $32.4 million, after deducting underwriting discounts and commissions (but before deducting estimated offering expenses payable by the Company). Viveve intends to use the net proceeds from this offering for supporting the commercialization of its products, clinical research and development, working capital and general corporate purposes. All shares sold in the offering were sold by Viveve.




Viveve to Present at Leerink Global Healthcare Conference

Fri, 09 Feb 2018 08:28:00 EST

ENGLEWOOD, CO--(Marketwired - February 09, 2018) - Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that Patricia Scheller, chief executive officer and director, will present at the 2018 Leerink Global Healthcare Conference on Thursday, February 15th at 2:00PM ET in New York City. Ms. Scheller will provide an update on the company's global development strategies and commercialization efforts in the United States and abroad.




Viveve Announces Pricing of Public Offering of Shares of Common Stock

Thu, 08 Feb 2018 08:01:00 EST

ENGLEWOOD, CO--(Marketwired - February 08, 2018) - Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced the pricing of an underwritten public offering of 10,000,000 shares of its common stock at a public offering price of $3.00 per share. In addition, Viveve has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the public offering price. The offering is expected to close on or about February 12, 2018, subject to the satisfaction of customary closing conditions. Viveve intends to use the net proceeds from this offering for supporting the commercialization of its products, clinical research and development, working capital and general corporate purposes.




Viveve Announces Proposed Public Offering of Shares of Common Stock

Wed, 07 Feb 2018 16:01:00 EST

ENGLEWOOD, CO--(Marketwired - February 07, 2018) - Viveve Medical, Inc. ("Viveve") (NASDAQ: VIVE), a medical technology company focused on women's intimate health, today announced that it has commenced an underwritten public offering of shares of its common stock. All shares of common stock will be offered by Viveve. Viveve expects to grant the underwriters a 30-day option to purchase up to an additional 15% of shares of common stock in connection with the public offering. Viveve intends to use the net proceeds from this offering for supporting the commercialization of its products, clinical research and development, working capital and general corporate purposes.




University of Rochester Initial Research Study Patients Completed

Wed, 07 Feb 2018 09:41:39 EST

VANCOUVER, BC and BOSTON, MA--(Marketwired - February 07, 2018) - Imagin Medical (CSE: IME) (CSE: IME.CN) (CNSX: IME) (OTC PINK: IMEXF) (FRANKFURT: DPD2) (STUT: DPD2) (the "Company"), as a follow-up to the announcement dated January 22, released additional information concerning the research study being conducted at the University of Rochester Medical Center using the i/Blue Imaging System.